BioSpace News Archive

Now that Sirona Biochem has closed an exclusive global licencing agreement with Allergan Aesthetics, the next steps for sustainable and rapid growth of the company are initiated.

Johnson & Johnson Vision announced it has received U.S. Food & Drug Administration clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL.

Inflammatix, Inc., a pioneering molecular diagnostics company, announced today the appointment of Purvesh Khatri, PhD, as Chief Scientific Officer.

Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations and a live case transmission featuring the company’s Lumivascular technology at the Leipzig Interventional Course (LINC) 2022.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease.

PulmoSeekTM Lung Cancer Early Detection Assay, the non-invasive blood-based cfDNA methylation detection product developed by AnchorDx for the early diagnosis of lung cancer, recently completed the procedure for EU IVDD CE Marking, and obtained IVD reagents licensing signed and issued by the CIBG of Ministry of Health, Welfare and Sport in the Netherlands.

Halia Therapeutics , a clinical-stage biotechnology company discovering and developing small molecule therapeutics to treat inflammatory diseases, today announced that the first participant in a Phase 1 clinical study has been dosed with HT-6184, a novel small molecule inhibitor of NEK7 and the NLRP3 pathway.

GI Dynamics announced results from a multicenter study evaluating GI Dynamic’s EndoBarrier® System intended for patients who do not have adequate control of their type 2 diabetes and obesity through their current medication and lifestyle.

Coya Therapeutics, Inc. (Coya), today announced the execution of an option agreement for exclusive worldwide rights to a novel and proprietary technology platform enabling exosome engineering from Carnegie Mellon University.

Ricoh USA, Inc. today announced RICOH 3D for Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its craniomaxillofacial (CMF) and orthopedic patient-specific anatomic modeling.